|
MTHFD2-Targeting Peptide Decoy for Chemotherapy-Resistant Cancers
Application
An engineered decoy peptide, DMp39, targeting DLAT-MTHFD2 interaction, as a sensitizer for chemotherapy resistant cancer treatment.
Key Benefits
Restores chemotherapy sensitivity in resistant tumors.
Targets the DLAT-MTHFD2 pathway with high specificity and minimal off-target toxicity.
Market Summary
Chemotherapy resistance remains...
Published: 6/15/2026
Contributor(s): Sumin Kang, Jung Seok Hwang, Jaehyun Kim
|
|
DNA EndosomaL Escape Vehicle Response (DELVR) as a Platform to Boost Antisense Oligonucleotide (ASO) Efficacy
Application
A versatile delivery platform for antisense oligonucleotides (ASOs) enabling transient downregulation of protein expression.
Key Benefits
Broadly boost the efficacy of nucleic acid-based drugs.
Drastic reduction in toxicity.
DELVR strategy can rescue clinically tested ASOs that didn’t progress to FDA approval due to off-target...
Published: 5/22/2026
Contributor(s): Steven Narum, Khalid Salaita
|
|
c‑Abl Modulators for Neurodegenerative Disease Treatment
Application
Small‑molecule c‑Abl inhibitors designed to treat neurodegenerative diseases such as Parkinson’s and Alzheimer’s.
Key Benefits
Targets c‑Abl, a key regulator linked to neurodegeneration, oxidative stress, and loss of dopaminergic neurons.
Provides new small‑molecule scaffolds with potential for improved safety profiles...
Published: 3/2/2026
Contributor(s): Thomas Kaiser, Zackery Dentmon, Christopher Dalloul, Dennis Liotta
|
|
Precision Neo-Cysteine Molecular Glues to Restore Protein-Protein Interactions in Disease
Application
Molecular glues designed to selectively bind mutated neo-cysteine residues and restore disease-disrupted protein–protein interactions (PPIs), offering a precision therapeutic approach for conditions such as cancer where loss or weakening of critical protein interactions drives tumor growth and progression.
Key Benefits
Provides...
Published: 6/15/2026
Contributor(s): Xiulei Mo, Haian Fu
|
|
Targeted Candidalysin Binders for Fungal Infection Control
Application
A theranostic scaffold-derived protein that neutralizes candidalysin toxin.
Key Benefits
Different mechanism of action compared to current antifungal drugs, reducing the risk of resistance.
Derived from human protein for lower immune response and produced cost-effectively in simple bacterial media.
Small size improves tissue penetration...
Published: 4/27/2026
Contributor(s): Sohail Khoshnevis, Eric J. Sundberg, Maros Huliciak
|
|
Methioninase Inducing Virus for Anti-Cancer Therapy
Application
A set of viral constructs that induce regulatable expression of methionine degrading enzyme for treatment of brain tumors.
Key Benefits
Built-in Tet-responsive element ensures precise regulation, preventing unwanted enzyme activity.
IL-2 signal directs the enzyme for secretion, optimizing its therapeutic impact.
Specific delivery...
Published: 6/15/2026
Contributor(s): Leon McSwain, Andrey Tikunov, Timothy R. Gershon
|
|
Small Molecule Inhibitors Targeting OTUD4-CD73 Interaction for Immune-Cold Tumors
Application
This technology introduces small molecule inhibitors, ST80 and Z22, to disrupt the protein-protein interaction (PPI) between OTUD4 and CD73. These inhibitors enhance tumor immunogenicity by reducing CD73 stabilization, improving the immune response in triple-negative breast cancer (TNBC) and other immune-cold tumors.
Key Benefits
ST80...
Published: 5/22/2026
Contributor(s): Yong Wan, Yueming Zhu, Ivet Bahar, Anupam Banerjee, Jiyoung Lee
|
